Development of docetaxel in advanced non-small-cell lung cancer

被引:15
作者
Belani, CP
Eckardt, J
机构
[1] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Inst Canc, Lung & Thorac Canc Program, Pittsburgh, PA 15260 USA
[3] Canc Res Ctr, St Louis, MO USA
关键词
non-small-cell lung cancer; docetaxel; taxane;
D O I
10.1016/S0169-5002(04)80036-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Docetaxel, a semisynthetic taxane initially developed for the treatment of breast cancer, has a high degree of activity in lung cancer. Although the mechanisms of action of the taxanes docetaxel and paclitaxel are identical, docetaxel has almost a twofold higher binding affinity for the target site, beta tubulin. In clinical trials, individuals previously treated with paclitaxel benefited from docetaxel. Docetaxel is the standard of care in second-line therapy of advanced non-small-cell lung cancer (NSCLC) and is effective, alone and in combination, in first-line treatment of advanced NSCLC. The standard in first-line therapy of metastatic NSCLC is a platinum doublet with one of the third-generation chemotherapy agents, docetaxel, paclitaxel, gemcitabine, or vinorelbine. Each of these doublets offers similar therapeutic benefit. In a phase-III study comparing docetaxel-cisplatin and docetaxel-carboplatin with vinorelbine-cisplatin, patients treated in the two docetaxel arms had consistently improved global QoL compared to patients treated with the vinorelbine-cisplatin doublet. This landmark study Led to Food and Drug Administration (FDA) approval of cisplatin-docetaxel for the treatment of advanced NSCLC. Non-platinum doublets such as docetaxel-gemcitabine have also demonstrated efficacy and safety. Docetaxel. has undergone extensive evaluation and is the only agent approved for use in both first- and second-line therapy of advanced NSCLC. (C) 2004 Elsevier Science Ltd.
引用
收藏
页码:S3 / S11
页数:9
相关论文
共 37 条
[11]   Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens [J].
Fossella, FV ;
DeVore, R ;
Kerr, RN ;
Crawford, J ;
Natale, RR ;
Dunphy, F ;
Kalman, L ;
Miller, V ;
Lee, JS ;
Moore, M ;
Gandara, D ;
Karp, D ;
Vokes, E ;
Kris, M ;
Kim, Y ;
Gamza, F ;
Hammershaimb, L .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) :2354-2362
[12]  
Gandara David R, 2003, J Clin Oncol, V21, P2004, DOI 10.1200/JCO.2003.04.197
[13]   Activity of docetaxel in platinum-treated non-small-cell lung cancer: Results of a phase II multicenter trial [J].
Gandara, DR ;
Vokes, E ;
Green, M ;
Bonomi, P ;
Devore, R ;
Comis, R ;
Carbone, D ;
Karp, D ;
Belani, C .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :131-135
[14]  
Georgoulias V, 2003, Clin Lung Cancer, V4, P288, DOI 10.3816/CLC.2003.n.008
[15]   Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial [J].
Georgoulias, V ;
Papadakis, E ;
Alexopoulos, A ;
Tsiafaki, X ;
Rapti, A ;
Veslemes, M ;
Palamidas, P ;
Vlachonikolis, I .
LANCET, 2001, 357 (9267) :1478-1484
[16]  
HESKETH PJ, 2004, P SOC AM ONCOL, V23, P627
[17]  
KAKOLYRIS S, 2002, P AN M AM SOC CLIN, V21, pA296
[18]   Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: The Japanese taxotere lung cancer study group [J].
Kubota, K ;
Watanabe, K ;
Kunitoh, H ;
Noda, K ;
Ichinose, Y ;
Katakami, N ;
Sugiura, T ;
Kawahara, M ;
Yokoyama, A ;
Yokota, S ;
Yoneda, S ;
Matsui, K ;
Kudo, S ;
Shibuya, M ;
Isobe, T ;
Segawa, Y ;
Nishiwaki, Y ;
Ohashi, Y ;
Niitani, H .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (02) :254-261
[19]  
LILENBAUM R, 2004, P SOC AM ONCOL, V23, P27
[20]  
LORIGAN P, 2004, P SOC AM ONCOL, V23, P629